[{"address1": "9804 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "240 552 8181", "website": "https://www.regenxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 353, "companyOfficers": [{"maxAge": 1, "name": "Mr. Curran M. Simpson M.S.", "age": 63, "title": "President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 881250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mitchell  Chan M.B.A.", "age": 44, "title": "Executive VP & CFO", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 205311, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Olivier  Danos Ph.D.", "age": 67, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 770124, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick J. Christmas II, J.D.", "age": 54, "title": "Executive VP & Chief Strategy and Legal Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 723558, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen  Pakola M.D.", "age": 56, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 750334, "exercisedValue": 78685, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Craig  Malzahn", "title": "Executive VP of Product Development & CTO", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shiva G. Fritsch", "title": "Chief Communications & People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sarah  Thomas", "title": "Senior Vice President of Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ram  Palanki Pharm.D.", "age": 49, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jahannaz  Dastgir D.O.", "title": "Clinical Development Lead", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 11.6, "open": 11.23, "dayLow": 10.97, "dayHigh": 11.56, "regularMarketPreviousClose": 11.6, "regularMarketOpen": 11.23, "regularMarketDayLow": 10.97, "regularMarketDayHigh": 11.56, "payoutRatio": 0.0, "beta": 1.068, "forwardPE": -5.4010887, "volume": 1009403, "regularMarketVolume": 1009403, "averageVolume": 793100, "averageVolume10days": 1387820, "averageDailyVolume10Day": 1387820, "bid": 8.18, "ask": 14.06, "bidSize": 2, "askSize": 2, "marketCap": 564953664, "fiftyTwoWeekLow": 5.035, "fiftyTwoWeekHigh": 16.19, "allTimeHigh": 85.1, "allTimeLow": 5.035, "priceToSalesTrailing12Months": 3.5021117, "fiftyDayAverage": 13.5011, "twoHundredDayAverage": 10.497475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 558888640, "profitMargins": -1.10288, "floatShares": 41744809, "sharesOutstanding": 50623086, "sharesShort": 5123815, "sharesShortPriorMonth": 5107325, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.1012, "heldPercentInsiders": 0.07936, "heldPercentInstitutions": 0.84721, "shortRatio": 6.85, "shortPercentOfFloat": 0.1229, "impliedSharesOutstanding": 50623086, "bookValue": 3.19, "priceToBook": 3.4984324, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -177915008, "trailingEps": -3.46, "forwardEps": -2.06625, "enterpriseToRevenue": 3.465, "enterpriseToEbitda": -4.016, "52WeekChange": 0.42710996, "SandP52WeekChange": 0.1575526, "quoteType": "EQUITY", "currentPrice": 11.16, "targetHighPrice": 52.0, "targetLowPrice": 14.0, "targetMeanPrice": 31.0, "targetMedianPrice": 29.0, "recommendationMean": 1.54545, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 274204992, "totalCashPerShare": 5.417, "ebitda": -139160992, "totalDebt": 268140000, "quickRatio": 2.55, "currentRatio": 2.665, "totalRevenue": 161318000, "debtToEquity": 166.08, "revenuePerShare": 3.141, "returnOnAssets": -0.18544, "returnOnEquity": -0.76875, "grossProfits": -78438000, "freeCashflow": -69017376, "operatingCashflow": -103297000, "revenueGrowth": 0.229, "grossMargins": -0.48623002, "ebitdaMargins": -0.86265, "operatingMargins": -1.76272, "financialCurrency": "USD", "symbol": "RGNX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1769819922, "regularMarketTime": 1769806802, "exchange": "NMS", "messageBoardId": "finmb_130641748", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -3.793108, "regularMarketPrice": 11.16, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 793100, "fiftyTwoWeekLowChange": 6.125, "fiftyTwoWeekLowChangePercent": 1.2164847, "fiftyTwoWeekRange": "5.035 - 16.19", "fiftyTwoWeekHighChange": -5.0300007, "fiftyTwoWeekHighChangePercent": -0.31068563, "fiftyTwoWeekChangePercent": 42.710995, "earningsTimestamp": 1762435800, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "earningsCallTimestampStart": 1762434000, "earningsCallTimestampEnd": 1762434000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.46, "epsForward": -2.06625, "epsCurrentYear": -3.2395, "priceEpsCurrentYear": -3.444976, "fiftyDayAverageChange": -2.3410997, "fiftyDayAverageChangePercent": -0.17340067, "twoHundredDayAverageChange": 0.6625252, "twoHundredDayAverageChangePercent": 0.06311282, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1442496600000, "postMarketChangePercent": 1.5232981, "postMarketPrice": 11.33, "postMarketChange": 0.17000008, "regularMarketChange": -0.44000053, "regularMarketDayRange": "10.97 - 11.56", "cryptoTradeable": false, "marketState": "CLOSED", "shortName": "REGENXBIO Inc.", "longName": "REGENXBIO Inc.", "displayName": "REGENXBIO", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]